09.04.2018 Issue 417

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Article: Mandated Prices in Drug Ads
a Legal Minefield

Wednesday, August 29

As the federal government’s interest continues to grow over the idea of requiring drugmakers to list prices in direct-to-consumers advertisements, any such action could open the door to a wave of legal and Constitutional challenges.

ICER: List Price of Patisiran for Amyloidosis Exceeds Standard Cost-Effectiveness Levels

Abilify MyCite ‘Digital Pill’ to Roll Out Soon

Arnold: A New Model Could Change Opinion of PBMs

ISPOR Honored for Branding Video, Conference Videos

MAPS Sponsoring PharmaTimes Medical and Scientific Excellence Awards

CMS Eases Rules on Part D to Facilitate Indication-Based Coverage

Associate Director Health Economics

Associate Director Real World Evidence (RWE) and Epidemiology

Associate Director/ Director, Medical Affairs- HEOR

Watson Health - Outcomes Research Leader (HEOR)

Senior Research Analyst - HEOR

Senior Director, HEOR Oncology & Specialty - 1850018301

Adjunct Faculty, Economics of Health Care, on-line

Watson Health - Lead Research Analyst (Outcomes Research)

Industry Spotlight

Conferences Webinars
Identifying Evidence for NICE Economic Submissions
    September 5, York, U.K.

22nd Annual Merck Technology Symposium
    September 5-6, Long Branch, New Jersey

ISPOR Asia Pacific 2018
    September 8-11, Tokyo, Japan

Orphan Drugs & Rare Diseases 2018 Americas East Coast
    September 10-12, Boston, Massachusetts

Digital Innovation in Clinical Trials
    September 11-12, Philadelphia, Pennsylvania

HIPAA Texting and Emailing: Myths vs Realities
    September 5

Building the Digital Infrastructure to Enable Genetic Medicine: Recommendations from a Multi-Stakeholder Summit
    September 7

PROving Its Worth: How to Develop a PRO Strategy to Distinguish Your Product with Regulators and Payers
    September 12

Review and Approval of Scientific Publications: Processes, Practices and Execution
    September 12

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Paying for Digital Health: Payer Insights

Benchmarking Pharma’s MSL Capabilities

Biosimilars: U.S. Payer Perspectives

A Holistic Approach to Payment Accuracy Helps Drive Cost Savings

Improving Patient Matching with a Simple Plug-In

Real-World Evidence in the Cloud: How Technology is Revealing the Big Picture in Pharma

How Payers Can Save an Average of $25,579 Per Patient by Eliminating Unwarranted, Non-Evidence-Based Cancer Treatment

ICER’s Reference Case for Economic Evaluations: Principles and Rationale

A Guide to Getting Started in HEOR/Market Access Medical Writing

Special Thanks to Our Partners:
            Evidera   HealthCore     University of FL
      Xcenda  OM1    Parexel   Jefferson   Dymaxium
      Precision Xtract    Pharmerit    eMax Health   Sciformix
      Evidence Partners    ICON    Truven